Neurogene Inc.

NASDAQ:NGNE

Biotechnology

Healthcare
$23.14 +2.47%

+$0.76 today

Market cap
$365.67M
Beta
2.04
P/E (TTM)
-7.1
EPS (TTM)
-$4.42
52W Low $14.65High $37.27

Volume 0.25M

Average 0.16M

NGNE Long-term Debt

Borrowings due after more than one year.

Neurogene Inc.NASDAQ: NGNE

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt remains negative

Q1 FY2026 long-term debt was $6.08M, compared with $0 a year earlier.

Context

  • Long-term debt amounted to 2.3% of total assets at the end of Q1 FY2026, up 2.3 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.08M— QoQ
Last fiscal yearDec 2025
$6.83M— YoY
Year agoMar 2025
$0— since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
6.83M USD
Year-over-year change
—

Long-term Debt vs competitors

How NGNE compares with its peers on the latest reported figures

  • NGNE's Mar 2026 long-term debt of $6.08M is the 4th highest of the 8 companies compared; the peer median is $4.67M.
  • Long-term debt amounts to 2.3% of total assets for NGNE, versus a peer median of 1.3%.
NGNE Competitors Peer median
Long-term Debt for NGNE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MGTXMeiraGTx Holdings plcMar 2026$49.7M -32.4%-11.2%20.3%
ALECAlector, Inc.Mar 2026$8.29M -12.4%—3.5%
TSHATaysha Gene Therapies, Inc.Jun 2026$6.29M -84.7%-21.8%1.3%
NGNENeurogene Inc.Mar 2026$6.08M ——2.3%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$4.67M ——1.9%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$0 ——0.0%
DSGNDesign Therapeutics, Inc.Mar 2026$0 ——0.0%
VYGRVoyager Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding NGNE) $4.67M-32.4%-16.5%1.3%

Competitors are the stored peer set for NGNE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents70.54M82.02M148.21M136.59M103.85M
Short-term Investments0048.95M175.82M165.17M
Net Receivables790K0600K648K0
Inventory1.91M0000
Other Current Assets(1.2M)1.62M1.1M981K2.76M
Total Current Assets73.96M84.72M200.35M315.92M271.77M
Property, Plant & Equipment (Net)27.53M24.55M20.95M18.49M15.46M
Goodwill00000
Intangible Assets128K0000
Long-term Investments878K0000
Tax Assets00000
Other Non-current Assets(1.01M)01.27M1.31M1.37M
Total Non-current Assets27.53M24.55M22.23M19.81M16.83M
Total Assets101.49M109.27M222.57M335.73M288.6M
Account Payables5.63M625K2.6M1.34M1.95M
Short-term Debt1.22M003M3.06M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities132K167K6.71M1.43M6.32M
Total Current Liabilities10.86M6.65M22.97M15.16M16.41M
Long-term Debt00006.83M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities177.91M0203K769K479K
Total Non-current Liabilities182.51M3.99M13.58M10.2M7.31M
Total Liabilities193.36M10.64M36.55M25.36M23.72M
Common Stock1K0000
Retained Earnings(95.65M)(150.84M)(187.15M)(262.3M)(352.65M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(91.88M)98.63M186.02M310.38M264.89M
Total Debt6.43M4.69M16.26M12.43M9.89M
Net Debt(64.11M)(77.33M)(131.96M)(124.16M)(93.95M)

Neurogene Inc.

NASDAQ:NGNE

Intrinsic Alpha fair value

Locked

Current Price

$23.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.